Abstract
Bone is an important organ that is essential to adult hematopoiesis, electrolyte balance, and locomotion. Individuals who have metastatic breast cancer involving the bone are at increased risk for skeletal complications and those who have a history of early-stage breast cancer may be at increased risk for fragility fractures. Maintaining bone integrity is critical to control the morbidity and mortality associated with fractures and other skeletal complications. The bisphosphonates have been shown to be efficacious in decreasing the risk for skeletal complications in cancer and in osteoporosis. The article reviews the use of bisphosphonates in patients who have breast cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Bone Density Conservation Agents / administration & dosage
-
Bone Density Conservation Agents / adverse effects
-
Bone Density Conservation Agents / pharmacology
-
Bone Density Conservation Agents / therapeutic use*
-
Bone Matrix / metabolism
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / pathology
-
Bone Resorption / metabolism*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Clinical Trials as Topic
-
Diphosphonates / administration & dosage
-
Diphosphonates / adverse effects
-
Diphosphonates / pharmacology
-
Diphosphonates / therapeutic use*
-
Female
-
Humans
-
Neoplasm Metastasis
Substances
-
Antineoplastic Agents
-
Bone Density Conservation Agents
-
Diphosphonates